Heron Therapeutics (HRTX) Proxy filing summary

Executive summary

• Annual Meeting scheduled for June 11, 2026, with virtual participation available to shareholders.

• Shareholders are encouraged to review proxy materials and vote by June 10, 2026.

Voting matters and shareholder proposals

• Election of seven director nominees to serve until the 2027 Annual Meeting.

• Ratification of Withum as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Advisory vote to approve compensation for Named Executive Officers for fiscal year ended December 31, 2025.

• Approval of amendment and restatement of the 2007 Equity Incentive Plan, increasing authorized shares by 16,560,000.

• Amendment to the 1997 Employee Stock Purchase Plan to increase authorized shares by 10,000,000.

• Advisory ratification of the adoption of the Tax Benefits Preservation Plan.

Board of directors and corporate governance

• Seven director nominees listed for election, including Craig Collard, Tom Cusack, Sharmila Dissanaike, Craig Johnson, Michael Kaseta, Adam Morgan, and Christian Waage.